Intellia Therapeutics Inc 's Revenue per employee fell on a trailing twelve month basis to $ 157,841, but the productivity of Intellia Therapeutics Inc 's employees remained above the company average.
Within the Healthcare sector Employees of 418 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 3134, from total ranking in previous quarter at 3651. Intellia Therapeutics Inc has 377 employees.

What is Sales per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Revenue per Employee▼

None ▼

Revenue per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NTLA Revenue per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Revenue Change	-46.23 %	-9.5 %	78.79 %	51.27 %	104.76 %
Sales per Employee (TTM) $	157,841	175,310	179,499	152,594	140,204
NTLA's Total Ranking	# 3134	# 3651	# 3296	# 3358	# 3450
Seq. Revenue Change	-49.1 %	-34.62 %	67.01 %	-3.25 %	-14.33 %

NTLA Company Profile >> Back to NTLA Efficiency Comparisons >> Compare NTLA Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 8
Healthcare Sector	# 419
Overall Market	# 3134

Revenue per Employee Statistics
High	Average	Low
$ 179,499	$ 114,305	$ 43,711
(Dec 31 2025)		(Dec 31 2016)

Financial Statements
Intellia Therapeutics Inc 's Revenue MRQ	$ 8 Millions	Visit NTLA's Income Statement
Intellia Therapeutics Inc 's Revenues TTM	$ 60 Millions	Visit NTLA's aggregate revenue growth
What are NTLA's Sales?		Visit NTLA's Sales by Segment

News about Intellia Therapeutics Inc Revenue per employee

Intellia Therapeutics Charts Ambitious Course for 2025: Prioritizing Late-Stage Programs and Strengthening Talent for CRISPR Innovation

Intellia Therapeutics Charts Ambitious Course for 2025: Prioritizing Late-Stage Programs and Strengthening Talent for CRISPR InnovationIn a bold move signaling its commitment to advancing groundbreaking gene editing technologies, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneer in CRISPR-based therapies, has unveiled its strategic priorities and key anticipated milestones for 2025. This announcement, made on January 9, 2025, focuses particularly on the company s late-stage programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z), marking a pivotal moment in its quest to revolutionize healthcare for patients globally.The firm s renewed focus on these advanced programs reflects an understanding of the pressing needs within the healthcare landscape, where innovative therapies can significantly alter the treatment paradigm for various diseases. By prioritizing NTLA-2002, an investigational therapy for hereditary angioedema targeting the production of bradykinin, and Nexiguran Ziclumeran (nex-z), a novel treatment for patients suffering from acute pain, Intellia aims to lead the charge in providing effective and transformative solutions.

Other Ratios
Intellia Therapeutics Inc 's Income per Employee
Employees in In Vitro & In Vivo Diagnostic Substances
In Vitro & In Vivo Diagnostic Substances Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
NTLA's Revenue per Employee versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for NTLA's Competitors
Revenue per Employee for NTLA's Suppliers
Revenue per Employee for NTLA's Customers

You may also want to know
NTLA's Sales Growth Rates	NTLA's Pe Price to earnings ratio	NTLA's Receivables Turnover Ratio	NTLA's Stock Quote
NTLA's Net Income Growth Rates	NTLA's Ps Price to Sales ratio	NTLA's Sales per Employee	NTLA's Asset Turnover Ratio
NTLA's Net Margin	NTLA's Pb Price to Book ratio	NTLA's Financial Strength Ratios	NTLA's Dividend Payout Ratio

Date modified: 2026-09-08T10:43:09+00:00

Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector	Revenue per Employee	Revenue 12 months ending Jun 30 2026	Number of Employees Jun 30 2026
Cv Sciences Inc	274,227.27	$ 12.066 Million	44
Cvrx inc	269,793.72	$ 60.164 Million	223
Lifeward ltd	269,407.41	$ 21.822 Million	81
Personalis Inc	267,957.69	$ 69.669 Million	260
Cytomx Therapeutics Inc	265,246.38	$ 18.302 Million	69
Revvity Inc	264,710.09	$ 2,911.811 Million	11,000
Arcturus Therapeutics Holdings Inc	264,576.58	$ 29.368 Million	111
Innovative Eyewear Inc	262,462.92	$ 3.412 Million	13
Surrozen Inc	261,613.64	$ 11.511 Million	44
Dentsply Sirona Inc	260,214.29	$ 3,643.000 Million	14,000
Harvard Bioscience Inc	260,070.80	$ 88.164 Million	339
Opko Health Inc	258,415.82	$ 587.896 Million	2,275
Vycor Medical Inc	258,210.43	$ 1.807 Million	7
Ardent Health Inc	254,203.97	$ 6,405.940 Million	25,200
Rosecliff Acquisition Corp I	253,338.46	$ 16.467 Million	65
Cryoport inc	252,644.99	$ 186.452 Million	738
Zai Lab Limited	252,025.78	$ 449.614 Million	1,784
Qhslab Inc	251,420.92	$ 3.017 Million	12
Brightspring Health Services Inc	250,124.17	$ 5,877.918 Million	23,500
Heartflow Inc	250,048.64	$ 210.791 Million	843
Mettler toledo International Inc	249,028.61	$ 4,133.875 Million	16,600
Voyager Therapeutics Inc	244,390.07	$ 34.459 Million	141
Establishment Labs Holdings Inc	244,128.49	$ 245.105 Million	1,004
Lifeloc Technologies Inc	243,928.87	$ 9.269 Million	38
Immunitybio inc	239,930.54	$ 165.792 Million	691
Envista Holdings Corporation	238,033.33	$ 2,856.400 Million	12,000
Aspira Women s Health inc	237,605.26	$ 9.029 Million	38
Nuwellis Inc	237,184.21	$ 9.013 Million	38
Neuronetics Inc	234,945.29	$ 154.594 Million	658
Ginkgo Bioworks Holdings Inc	230,645.36	$ 111.863 Million	485

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.